Six novel HLA-C variants with nucleotide changes in non-coding regions: HLA-C*04:32:01:02, -C*07:01:01:142, -C*08:04:01:05, -C*12:03:01:68, -C*12:03:01:69 and -C*16:01:01:41.
Six novel HLA-C variants with nucleotide changes in non-coding regions: HLA-C*04:32:01:02, -C*07:01:01:142, -C*08:04:01:05, -C*12:03:01:68, -C*12:03:01:69 and -C*16:01:01:41.
HLA-DPA1*02:139 and -DPA1*02:140N, two novel HLA-DPA1 alleles detected by next-generation sequencing.
HLA-A*32:01:56 differs from HLA-A-32:01:01 by a single nucleotide variation in Exon 5, codon 313.3.
HLA-DQA1*05:115 shows an alanine at position 59 not described previously.
One nucleotide deletion in codon 15 of HLA-B*40:01:02:01 results in a novel null allele, HLA-B*40:510N.
HLA-C*08:291, a novel HLA class I allele detected by next-generation sequencing.
HLA-DPB1*04:02:24 differs from HLA-DPB1*04:02:01:01 by a single synonmous nucleotide substitution at position 639 G>A.
HLA donor specific antibodies (DSA) are implicated in antibody-mediated rejection (AMR), graft dysfunction and failure in kidney transplant (KT) recipients. Non-HLA antibodies including angiotensin II type 1 receptor (AT1R) may also play a role in AMR, impact graft function and survival. Data is limited in paediatric KT cohorts. We aimed to assess the prevalence and effect of pre-transplant AT1R antibodies on rejection, graft function and survival in paediatric KT recipients. This was a retrospective cohort study conducted across two paediatric centres including KT recipients with a pre-transplant AT1R antibody level. Outcomes included rejection, de novo DSA formation, graft function, failure, proteinuria and hypertension. Of 71 individuals, 72% recorded a positive pre-transplant AT1R Ab level (≥17 U/mL). Over a median follow-up of 4.7 years, AT1R Ab positivity demonstrated a trend towards increased risk of rejection however was not statistically significant (HR 3.45, 95% CI 0.97–12.35, p-value 0.06). Sensitivity analysis with AT1R Ab levels of ≥25 U/mL (HR 2.05 95% CI 0.78–5.39, p-value 0.14) and ≥40 U/mL (HR 1.32, CI 95% 0.55–3.17, p-value 0.53) validated this. De novo DSA formation occurred more frequently with AT1R Ab positivity (41% vs. 20%, p-value 0.9). AT1R Ab was not associated with hypertension, proteinuria, graft failure or dysfunction. In conclusion, this cohort study demonstrated a high prevalence of pre-transplant AT1R Ab positivity (72%). AT1R Ab positivity demonstrated a trend towards increased risk of rejection and de novo DSA formation however did not meet statistical significance. There was no association between AT1R Ab and hypertension, proteinuria, graft failure or dysfunction.
The novel KIR2DL1*00308 allele differs from the closest allele KIR2DL1*00302 by a single sense mutation.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：